Australia's Future in Global Peptide Drug Development

Paul Watt, Chief Scientific Officer, Phylogica Ltd, Australia sat down with the TIDES team to discuss the future of global peptide drug development in Australia as well as the current challenges for intracellular drug delivery and the important roles that academic institutions have in the development and commercialization of peptide therapeutics. Below you will find a brief excerpt from this exclusive interview. To access the complete interview, click here.


In terms of investment and innovation, where do you see Australia's future in global peptide drug development?

Australians have had a long history in peptide discovery. For example the pioneering work of Professor Mario Geysen enabled the parallel synthesis of peptides in the early 80's. More recently Australia has accumulated multiple high achieving peptide scientists such as Paul Alewood (eg. synthesis toxin peptides including use of selenolanthionine bridges), Richard Lewis and Glenn King (ion channel active venom peptides) (including ion channel inhibitors). David Craik (cyclotides and structural biology of complex peptides), John Wade (neuropeptides/relaxins). Australian peptide innovation has been successfully commercialised with the establishment of multiple companies, including Mimotopes, Auspep, Protagonist and Phylogica. As many of these companies mature, I see a bright future in the development of the Australian peptide industry. In addition several peptides discovered in Australia have been subject of multiple alliances with big Pharma offering further commercial potential as they progress through clinical development.


To learn more from Paul, join him at TIDES, May 9-12, 2016 in Long Beach, CA. Where he will be discussing how to design oligonucleotides with better drug-like properties to accelerate your products from discovery/preclinical to the clinic and to market.  

Register for TIDES now and save $100, use the code B16180BLOG100.

Share this article with your social network, just click below to share now!

Share |

Peptides for CNS and Alzheimer's Disease Therapy

Exclusive TIDES 2016 interview with Dieter Willbold, Ph.D., Director, ICS-6 Structural Biochemistry, Forschungszentrum Jülich, Germany. Dr. Willbold gives us some exclusive insights into the topics he will be addressing onstage at the 18th annual TIDES in just 4 weeks time. Don't miss out on this record setting meeting; join over 800 global attendees over 4 days full of insights and learnings. Register for TIDES by Friday, 4/15 and save $300 - Use the code B16180BLOG.


Dr. Willbold Interview: 

What current challenges are you facing for advancing your promising peptide for Alzheimer's disease through clinical trials?

Our main focus at the moment is to finish all the necessary preclinical tox and safety tests in order to soon get permission for a clinical phase I study with our drug candidate.

One challenge for developing therapeutics like ours that target specific aggregate species, lies in the lack of suitable analytics to measure target engagement, because most methods don't differentiate between different aggregate sizes. In addition to cognitive behavioral tests, we ourselves have therefore developed novel methods to measure efficacy and target engagement .e.g. QIAD (short for quantitative determination of interference with aggregate size distribution; Brener et al., Scientific Reports 2015), which measures Abeta oligomer elimination efficiency.


What are the advantages of peptide therapeutics over small molecules, antibodies and other protein therapeutics?

Small molecules often lack specificity, and this can lead to serious side effects and autoimmune responses. On the other hand protein-based therapeutics like antibodies possess high target selectivity and are made of natural components, but they are very big and expensive molecules. They often suffer from low oral bioavailability.

Small peptides can offer the best of both worlds in some respects: They are more target specific than small molecules but easier to produce than protein based drugs. Our drug candidate is made solely from D-enantiomeric amino acid residues and has surprisingly good oral bioavailability.


Where do you see innovation happening in the peptide field over the next 5 years?

Innovation will certainly happen in the production of peptides (cost reduction) and in the formulation of peptides (increase oral bioavailability).

______________________________________________________

Reserve your seat today to attend TIDES 2016 in Long Beach, CA and hear Dr. Willbold deliver a live presentation "Efficiency and Oral Bioavailability of Abeta Oligomer Directed D-Enantiomeric Peptides Developed for Therapy of Alzheimer's Disease", where he will delve into small soluble Abeta oligomers are suspected to be the major toxic species responsible for development and progression of Alzheimer's disease (AD). We developed highly potent D-enantiomeric peptide compounds that specifically eliminate Abeta oligomers and improve cognitive performance and stop or slow down neurodegeneration of AD transgenic mice. Data on stability and oral bioavailability clearly support the superiority of D-peptides over L-peptides.

Share this article with your social network, just click below to share now!

Share |

Record Attendance Expected! Don't Miss IBC's 18th Annual TIDES

Register by Friday, April 15th and save $300! To save, use the code B16180BLOG100

Experts Provide Key Success Factors for Drug Development and Manufacturing:

Mixed-Incretin Receptor Biochemical Signaling at Multiple Receptors
Richard DiMarchi, Ph.D. Standiford H. Cox Professor of Chemistry, Indiana University

Drisapersen: Case Study
Robert Baffi, Ph.D. Executive VP, Technical Operations, BioMarin Pharmaceuticals

Quark's Long History of Oligonucleotide Development
Danny Zurr, Ph.D. Chairman and CEO, Quark Pharmaceuticals Inc. 

Technologies for Targeting Molecules to Sites of Diseases
John Reed MD, Ph.D Global Head of Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.


TIDES 2016 is on pace for record attendance with 800+ global attendees expected to attend this year’s meeting, held May 9-12, 2016 in Long Beach, California – will you be there?

Register your team today and access the science, technologies and contracts you need to accelerate your oligonucleotide and peptide products through the clinic towards commercial success.

Your registration grants you access to:

• 800+ attendees representing 25 countries help you forge new business and scientific collaborations
• 100+ speaker presentations across 5 tracks provide a customized agenda of solutions for your company’s current challenges
• 70+ exhibitors demonstrate the latest products and technologies to accelerate your therapeutic to market
• 40+ poster presentations keep you abreast of cutting-edge industry and academic research

Plus, be sure to register this week to gain access to Attendee Connect powered by partneringONE, the digital networking platform that allows you to view the full attendee list, pre-schedule meetings, and send private messages to attendees before, during and after the event.

Share this article with your social network, just click below to share now!

Share |

Exclusive Interview with Dr. Bruce Riser, CEO, BLR-Bio, LLC

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Bruce L. Riser, Ph.D., CEO, BLR-Bio, LLC for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.

What are the biggest challenges of bringing new agents with novel targets to the market?

BR: There are really two big challenges when bringing new agents with novel targets to the market. First, many investors and potential partners are not familiar with the target, or they do not have the comfort that exists with an established target. Second, there can be misperceptions in the scientific community and in the biopharmaceutical industry where an agent is associated with another type of development creating a negative halo. On the first challenge, it is easy to see a proven target and to line up, jumping on the bandwagon with others trying to either win the race to launch first or to attempt to find a niche in an already established area. The problem of course is that lining up with everyone else does not provide the opportunity to develop and launch a true breakthrough therapy that can change the treatment paradigms and have a breakthrough impact on peoples' lives. Instead, investors and companies that line up for the established target often find they are trailing others to the market and are never able to successfully establish themselves in the market. It really takes a visionary to see the potential of a new target and have the insight and strength to invest in it. The second challenge, dealing with miss-associations of a novel therapy with other developments can be truly vexing. Our peptides target the novel CCN signaling pathway, leveraging the unique qualities of CCN3 to target the control of ECM changes in response to injury, blocking fibrosis and creating an environment for re-establishment of complete tissue homeostasis. By creating peptide libraries and conducting diverse in vitro and in vivo screens we have identified specific regions with the CCN3 protein responsible for blocking single, or multiple, pathways to fibroblast and cancer growth, and fibrosis formation. Unlike other products such as antibodies directed against the pro-fibrotic CCN2, that appear to partially block a single pathway, our novel therapy regulates vs. simply blocking, thus allowing reestablishment of the body's healthy equilibrium.

With several peptide products in the pipeline in preclinical development and a wide range of possible disease applications, how have you selected your lead indication target(s)?

BR: Having several products covering a wide variety of diseases is great and choosing lead indications to pursue is a wonderful challenge to have. In reality, the two lead indications that we have chosen to pursue have as much to do with the research that we have done with my team as it does the extreme health care need. My long background in academia, clinical nephrology/public health, and pharmaceutical drug R&D has driven the way we do drug discovery at BLR Bio. First, working to clearly understand the pathways to disease before selecting a target, and trying not to get caught up by targets in vogue. Then, testing our peptides in multiple related diseases before moving into the clinic. Our pipeline was created out of our long-term interest in fibrosis and the extracellular matrix in biology and disease, particularly in renal fibrosis as a complication of diabetes an area of great medical need. This has led to the selection of diabetic nephropathy as a main target for one of our lead products. Since our target, and the peptide inhibitor of our target, are involved in many other forms of fibrosis and other disease involving the miss-regulation of matricellular signaling, this creates other exciting therapeutic indications down the road. These include NASH, IPF, MD, and scleroderma to name a few.

I began my career in cancer research, and we know now that the extracellular matrix and matricellular signaling proteins such as the CCNs are critical also in the formation and resolution of tumors. The pro-fibrotic CCNs, CCN2 and CCN4 in particular have been shown to be important for the establishment and likely invasion and metastases in numerous tumors. The opportunity to use CCN3-based therapy to, not only halt the cancer, but also to target the microenvironment is an exciting one. Our company is particularly excited about the potential in pancreatic cancer. We have an established relationship with thought leaders in the cancer field and are moving forward with development work, partnering with some of these world experts. To add to the excitement of the therapies, our company also is developing a diagnostic/theranostic based on the same technology platform. It holds the promise of either stand-alone or companion diagnostics for development.

What are the key advantages of peptide therapeutics over small molecules, antibodies and other protein therapeutics?

BR: As you know, peptide-based drugs are one of the most rapidly growing areas in therapeutic development. More than 100 peptide-based drugs are on the market with several effective in cancer treatment. There is good reason for this. In size, falling between small molecule drugs and "biologics", they have many of the benefits of both while shedding many of the deficiencies. For example, because of their small size they gain many delivery benefits over biologics. First, better penetration of tissue at the site of action. This is crucial in fibrotic disease and cancer where there is a very strong barrier to penetration. Second, it allows for many more delivery options, including oral formulation. The earlier assumption of poor metabolic stability of peptides has just not proven to be the case. Although there is often rapid clearance from circulation, the previous assumptions about required PK by classic definition has also proven to be not relevant, since a specific and sustained biological activity at the target receptor is characteristic of many peptides. Unlike small molecules they are based on sequences that have evolved to react with specific receptors and often at very low concentrations. This results in very low off target effects. Last, since they can be chemically synthesized the ease and cost to manufacture are more nearly like that of small molecules. The majority of approved peptides are in the 15 amino acids (aa) range or smaller, and they treat a broad range of diseases.

How do you see academia and industry collaborating in the future to advance promising peptide therapeutics into commercially viable products?

BR: First, we think that academia will play a significant role in the creation of new peptide-based therapies in the future. Since the last decade has seen a decline in the number of newly approved drugs from large pharma, and recently there has been a strong trend for these same companies to dramatically reduce their discovery effort, this creates a large opportunity for novel peptide therapies and academic-initiated translational research. This does not necessarily mean that the new paradigm will be that large strategic companies will license early stage assets directly from Universities. Rather, we anticipate that the most promising discoveries will lead to the creation of start-up companies and the building of defendable IP. Then, large pharmaceuticals will court these start-ups as they progress to become true biotechnology companies with completion of phase I, phase II clinical trials or beyond. We think that the best of these emerging biotech companies will then expand their ability to do discovery and early stage development. They will also be able to clearly evaluate and in-license additional opportunities in academia. These are exactly the skills now lacking in big pharma. These successful discovery biotech's will become the future pipelines for drugs that will go to the mid and large pharma companies centered on late development and marketing. I envision BLR Bio as becoming one of these discovery companies able to contribute significantly to filling this gap.

Want to hear more from Dr. Riser? Join him this May in Long Beach, CA for the 18th annual TIDES - Save $300 when you register using the code B16180BLOG100. Click here to register. 

Share this article with your social network, just click below to share now!

Share |

The Current Value of the Global Peptide Therapeutics Market

"The number of companies specializing in the manufacture of therapeutic peptides has been shrinking over the last 15 years with fewer new companies entering the market than those leaving it."  

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA. 


In this interview, Dr. Lax discusses:

• - The current estimated value of the global peptide therapeutics market.
• - The key factors that contribute to the constant growth of the global peptide therapeutics market.
• - The advantages/disadvantages to a consolidated peptide manufacturing industry.
• - Which emerging markets are leading the forefront of peptide therapeutics research and development
• - Opportunities that are emerging due to recent advancements in manufacturing and delivery technology

 Access the complete interview here.

PLUS! As a blog reader, you are eligible to save $300 when registering for TIDES. Use the code B16180BLOG100 to activate your savings. Click here to register.

Share this article with your social network, just click below to share now!

Share |

Analytical Controls in an Evolving Technology and Regulatory Landscape

 
IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Rachel Orr, Senior Scientist, GlaxoSmithKline R&D, United Kingdom for an exclusive interview that delves into analytical controls in an evolving technology and regulatory landscape, the topic of her presentation at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.


1. What key analytical challenges do oligonucleotide developers need to overcome in order to achieve regulatory approval?

Oligonucleotides are inherently difficult to analyze - they are neither traditional, small nor large molecules, and the techniques and well established methodologies for pharmaceutical analysis are all focused on these distinct classes. In addition, there is very limited regulatory guidance when it comes to oligonucleotides, so there are no set rules to follow. There are often discussions as to whether oligonucleotide analysis should follow small molecule rules and regulations or align with biopharmaceuticals; opinions are divided.

With limited experience across the industry in marketing applications it is difficult to assess what is needed in order to gain regulatory approval and this is one of the biggest challenges in CMC oligonucleotide development. There is no recent precedence of global oligonucleotide marketing applications and as such it is difficult to ascertain what may and may not be acceptable. Close engagement with the regulators is something which helps to form strategies and controls and hopefully this will increase the likelihood of success of regulatory approvals going forwards.


2. How have advancements in technology improved the analytical process? Can you provide examples?

Since the last successful oligonucleotide marketing application there have been considerable enhancements in technologies. UHPLC is now common throughout the industry and techniques such as high resolution NMR and mass spectrometry are much more affordable and quick. These advances in technology mean that the resolution and robustness of methodologies can be much improved, however has a downside that the regulators may well expect us to present them with these improvements by first intent.

Increased understanding of non "typical" molecules throughout the industry has enabled wider thinking and collaboration between different pharmaceutical companies, with more people working together on the problem progress will inevitably come quicker. As more people engage with the concept of oligos and as technology continues to evolve, I anticipate a large shift in the way we look to control oligonucleotides analytically in coming years.


3. What are the most common mistakes that oligonucleotide drug developers encounter during CMC submissions?

Again, due to there being so few oligonucleotides which have gone through the full CMC process I think it is difficult to make too many sweeping statements, however the key issues that I have come across all stem from attempting to fit oligonucleotides into a box. Whether it is the small molecule group or the biopharmaceutical groups who take on the challenge of oligonucleotides, it is generally only a few "experts" within that team who work on the molecules. It is impossible to fit existing small or large molecule platforms onto oligonucleotides and a lot of time, resources and money can be wasted trying to do so! Due to the small pool of people working on the oligo projects it can also be challenging when it comes to elements such as wider reviews of submissions as the reviewers are not always as well informed about the challenges associated with oligonucleotide analysis. Education of these reviewers and key stakeholders is an activity that cannot be underestimated in time or importance! This emphasizes the benefits of cross-pharmaceutical company collaborations.


Want to hear more from industry experts like Rachel? See our exclusive TIDES speaker Q&A series here.

Share this article with your social network, just click below to share now!

Share |

Accelerate Your Peptide from Discovery to Commercialization

Accelerate your peptide product from early discovery through late-stage development and commercialization by attending IBC's 18th Annual TIDES meeting, held May 9-12, 2016 in Long Beach, California.

TIDES offers two tracks dedicated for peptide scientists to learn about the latest strategies and technologies needed to overcome challenges in targeting, drug discovery and peptide design, process development, regulatory, scale-up manufacturing, investment landscape and more:

Keynote Speaker:
Richard DiMarchi, Standiford H. Cox Professor of Chemistry, Indiana University
Mixed-Incretin Receptor Biochemical Signaling at Multiple Receptors

Track 1: Peptide Chemistry, Manufacturing & Controls
Speaking Organizations Include: Lonza, Bachem, Teva, Novartis, Peptron

Track 2: Peptide Discovery, Preclinical and Clinical
Speaking Organizations Include: Corden, Galena, Neon, Celerion, Phylogica

Learn about the Therapeutic Landscape of Peptides in 2016 and Beyond:
Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group
Redefining the Therapeutic Peptide Business in the 21st Century

Plus, TIDES offers the largest and most focused exhibit hall for the peptide industry, where you can access 70+ vendor booths, 40+ posters and evening cocktail networking receptions to help grow your business. You won't want to miss out on this rare opportunity to connect with 800+ like-minded researchers from across the world.

As a reader of our blog, you are eligible to save $300 when registering for TIDES - Simply use the code B16180BLOG100. Click here to register.  

Share this article with your social network, just click below to share now!

Share |

Peptide Therapeutic Development in Korea

"Peptide therapeutics development in Korea has been focused on generic development, and peptide modification, or formulation technologies to make drugs have better pharmacokinetic properties, which result in the recent big license deal in this field in Korea."

Dong Seok Kim, Ph.D., Principal Scientist, Peptron, South Korea recently sat down with the TIDES team for an exclusive interview that previews some of the topics that will be discussed onsite this May.

In this interview, Dong Seok Kim discusses;

• The key regulatory challenges that peptide developers face
• The advantages of sustained release for oligonucleotide/peptide therapeutics
• South Korea's future in global peptide drug development

Drug Repositioning for Neurodegenerative Diseases using SR-Exenatide

SmartDepot™ is Peptron's proprietary technology for the sustained release (SR) microsphere formulations of various agents to provide once weekly or longer dosing regimens. Peptron is currently developing for T2DM a SR-Exenatide (once every two weeks), PT302, which is evaluated in a phase 2 clinical trials. The therapeutic potential of Exenatide in neurodegenerative disorders is being evaluated in various disease models such as AD, PD, and TBI. SR-Exenatide is expected to maximize therapeutic effects, increase drug compliance, and extend patent coverage.

Access the complete interview. 

Save $500 and register for TIDES before March 11th - To activate your savings, use the code B16180BLOG100

Share this article with your social network, just click below to share now!

Share |

From Critical Quality Attribute Assessment to Specification and Characterization

"The reason for assessing the critical quality attributes is not only to fulfill an expectation, but also because it serves as a better understanding of the product under development"

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Renata Varga, Ph.D., Scientist - Characterization, Analytical Sciences, Global Biological CMC, Teva Pharmaceutical for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.

In this interview, Dr. Varga discusses;

• The key regulatory challenges facing peptide developers
• What regulators look for when establishing CQAs in genetics, and any variation between generics and novel therapeutics.
• Peptide innovation in the next 5 years

From Critical Quality Attribute Assessment to Specification and Characterization
Characterization and comparability assessment of peptide based generic products is driven by critical quality attributes (CQAs). Standard CQAs are identified based on regulatory requirements. Additional CQAs are determined by understanding the molecule itself: sensitive amino acids or which are involved in receptor-binding or mechanism of activation, are identified and based on uncertainty and impact the criticality of that attribute is defined. All standard- and additional CQAs are included in the specification while potential CQAs are further characterized by orthogonal techniques.

Access the complete interview

Register for TIDES now and save $500 - to save, use the code B16180BLOG100

Share this article with your social network, just click below to share now!

Share |

Efficient Chemoenzymatic Peptide Synthesis (CEPS) in Water

"When peptides are ligated in water, the crude reaction mixture can immediately be loaded on the preparative HPLC column to purify the product" 

IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Timo Nuijens, Ph.D., Lead Scientist, EnzyPep BV, The Netherlands for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.

Efficient Chemoenzymatic Peptide Synthesis (CEPS) in Water
We describe a novel, organic cosolvent-stable peptide ligase (peptiligase), which couples peptide fragments with exceptional efficiency in water. Because peptiligase does not need a particular recognition motif, this novel technology is traceless and very broadly applicable. Besides fragment condensation, the enzyme is able to efficiently catalyze head-to-tail cyclization of peptides to create macrocyclics. It has also been shown to couple peptide esters efficiently to proteins. Peptiligase could be a useful tool for the (industrial) synthesis of numerous (pharmaceutical) peptides and conjugates.

In this interview, Dr. Nuijens also discusses;

• The importance of fragment condensation of peptides in water
• What the future holds for the Netherlands in the global peptide drug development market
• The factors to consider when determining the optimal synthesis strategy when screening an enzyme

Access the complete interview

Register for TIDES now and save $500 - To save, use the code B16180BLOG100

Share this article with your social network, just click below to share now!

Share |

Peptide Vaccine Manufacturing | Interview with Dr. Mimoun Ayoub of CordenPharma

"The concept of designing immunomodulating peptide cocktails and trigger the immune response has been mainly initiated by biotech companies who owns more than 80% of the current cancer vaccine pipeline."

In a recent interview with TIDES, Mimoun Ayoub, Ph.D., Director, Global Peptides & Injectables Platform, CordenPharma, Switzerland, shifts the focus towards the topics that will be addressed in his talk at the upcoming TIDES event. In his talk he will be examining the peptide vaccines that are designed to activate B-cells and killer T-cells to recognize cancer cells as foreign agents. Cancer cells have surface protein modifications such as phosphorylations and glycosylations that differentiate them from healthy cells. The peptide epitopes used are usually fragments from these modified proteins. These "cocktails" of peptide fragments can be further engineered to increase their immune activity and plasma half-life by constraining the peptide backbone through introduction of cyclization or non-natural amino acids in the sequence. The production and analytical challenges related to cocktail peptide vaccines will be discussed.

In the interview, Dr. Ayoub also addresses:

• The role peptide vaccines play in the in the development of novel cancer therapies
• Regulatory challenges during the development and manufacturing of peptide vaccine "cocktails"
• Future delivery methods for administering peptide vaccines

Access the complete interview

To learn more from Dr. Ayoub, join him at IBC's 18th Annual TIDES event this May in Long Beach, CA where he will be chairing the Peptide Chemistry Manufacturing and Controls track as well as speaking in a session titled "Peptide Vaccine Manufacturing : Drug Substance and Drug Product CMC Challenges" Download the brochure to access the complete agenda and speaking faculty. 


Register for TIDES now and save $500 - To activate your savings, use the code B16180BLOG100  

Share this article with your social network, just click below to share now!

Share |

Evaluating the Oligo and Peptide Market and Investment Landscape

The global oligonucleotide and peptide therapeutic market is experiencing rapid growth due to the constant development of new technologies, emerging markets and novel drug classes. Stay at the forefront of global investments, deals and developments in the oligonucleotide and peptide market by attending IBC's 18th Annual TIDES meeting, held May 9-12, 2016 in Long Beach, California.

Industry Experts Provide Updates on the Oligonucleotide and Peptide Market and Investment Landscape: 

1. The Oligo Therapeutics Market Landscape – A 15 Year Retrospective on Market Trends, Deals, Investments, and Key Clinical Developments with a Look to the Future Gary Carter, Director of Strategy and Marketing, Nucleic Acid Solutions Division, Agilent Technologies, Inc. Over the last 15 years the number of oligo therapeutic programs has grown from roughly 100 programs in 2002 to almost 300 in 2015, driven by the emergence of new classes such as siRNA, miRNA, and exon-skipping therapeutics, coupled with corresponding increases in direct investment and deal values. Read full abstract here.

2. Redefining the Therapeutic Peptide Business in the 21st Century Rodney Lax, Ph.D., Business Consultant, PolyPeptide Group The last 30 years has seen significant changes in our expectations for peptide therapeutics. While the peptide manufacturing industry has consolidated during that period, the complexity of the products themselves, the scale of manufacture, and number of potential delivery platforms have continually increased...(read full abstract here )

3. Personalized Medicine Patent Law Update Laura A. Labeots, Ph.D., J.D., Partner, Husch Blackwell Brief summary of Subject Matter Eligibility of patents based on natural products (35 USC 101) will be presented, along with discussion of practical implications of developing case law surrounding personalized medicine and nucleic acid diagnostics and therapeutics...(read full abstract here)

The #1 Meeting for Oligos and Peptides!

• 800+ attendees representing 25 countries help you forge new business and scientific collaborations;
• 100+ speaker presentations across 5 tracks provide a customized agenda of solutions for your company’s current challenges;
• 70+ exhibitors demonstrate the latest products and technologies to accelerate your therapeutic to market;
• 40+ poster presentations keep you abreast of cutting-edge industry and academic research

For full program details, download the TIDES 2016 brochure today!

Register by January 29 and Receive a $600 Savings! Use unique code B16180LINK100.

Best,
The TIDES 2016 Team

Visit the website.
Follow us on Twitter: @ibcusa #ibcTIDES
Read our blog: www.futurebiopharma.blogspot.com

Share this article with your social network, just click below to share now!

Share |

Are You Keeping Up with Your Competition at TIDES?

Over 70 leading and emerging oligonucleotide and peptide companies will be Exhibiting, providing cutting-edge Spotlight Presentations and/or Sponsoring networking sessions at TIDES 2015, coming to San Diego this May. What do they know?

They know:

·         TIDES is the largest gathering of the oligonucleotide and peptide community where networking and business gets done. Over 50% of the attendees are President’s, VPs, C-Level, Directors and Managers that hold the true buying decision power in their hands. Meeting face-to-face with these decision makers will accelerate business, partnerships and sales.

·         Whether in the Exhibit Hall, between sessions or during the scheduled Networking Receptions, you have direct access to hundreds of leading minds and businesses.

TIDES is the leading source of advances in technology, strategies and case studies that span from R&D through Commercialization. Your company needs to be an important part of this community and conversation.

Why let your competition have all the glory?

·         Secure one of the remaining 10 exhibit spaces left >> Request an updated floor plan

·         Sponsor a Spotlight Presentation and prove that your company is a thought-leader in the industry. We have a few select spots remaining in the agenda. Contact me for subject and topic areas.

·         Brand your company through sponsorship of the TIDES Lounge or other branding opportunities.

·         Capitalize on this unique opportunity to highlight your company's expertise to 800+ qualified attendees from 25+ countries.   As our valued event sponsor/exhibitor, your company's brand awareness extends beyond our attendees to our thousands of targeted email subscribers, website visitors and event prospects.   Give me a call or shoot me an email today to discuss how your participation at this year's TIDES meeting will help you achieve your company's targeted growth goals.

Join us in San Diego next month. Register for TIDES today: http://bit.ly/1OBPwgA

Best,
The TIDES Team

Futurebiopharma.blogspot.com

Share this article with your social network, just click below to share now!

Share |

Introducing TIDES: Oligonucleotide and Peptide® Therapeutics

Over the last 15 years, the TIDES Summit has cemented its status as the community’s premier meeting place for the oligonucleotide and peptide discovery, development and manufacturing industries.

Join 750 of professionals at this must attend oligonucleotide and peptide discovery, development and manufacturing event. This is your chance to get the information and contacts you need to overcome the toughest challenges you are facing and move your research, development and process chemistry.

View the full conference line-up. Download the agenda today!

Tides will take place May 12-15, 2013 in Boston.  If you'd like to join us, as a reader of this blog, you receive 20% off the standard rate when you register to join us and mention code TIDES13JP.  If you have any questions, feel free to email Jennifer Pereira.

Keynote Presentations Include:

• MIPOMERSEN CLINICAL ADVANCES
• ˃Presenter: Mary P. McGowan, M.D., Senior Medical Director, Clinical Research, Genzyme, A Sanofi Company
• EPITOPE TARGETING PCC AGENTS
• ˃Presenter: James R. Heath, Ph.D., Professor, Chemistry and Chemical Engineering, California Institute Of Technology
• SPHERICAL NUCLEIC ACIDS (SNAS)
• ˃Presenter: Chad A. Mirkin, Ph.D., Professor, Chemistry, Northwestern University
• VC FUNDING FOR OLIGOS AND PEPTIDES
• ˃Presenter: Bruce Booth, D.Phil., Partner, Life Sciences, Atlas Venture
• DELIVERY AND DEVICE STRATEGIES FOR PEPTIDES
• ˃Presenter: William J. Lambert, Ph.D., Fellow, Drug Delivery and Device Development, MedImmune, Inc.

Hear Comprehensive Updates Spanning the Entire Development Process:

• OLIGONUCLEOTIDE MANUFACTURING, TECHNOLOGY AND PRODUCT DEVELOPMENT
• • Hear first-hand reviews from regulatory and industry thought leaders on quality and purity specifications to answer your pressing questions about impurities specifications
• • Implement continued process verification with latest perspective of industry consortium
• • Modernize your process science with cutting-edge reports in the new process chemistry session
• PEPTIDE MANUFACTURING, TECHNOLOGY AND PRODUCT DEVELOPMENT
• • FDA perspective and scale up report on peptide vaccines
• • Plan for the future of novel synthesis technologies with new data from Lonza, Bachem and EMD
• • Learn how to assess and prevent aggregation to avoid late stage problems that can hold up product release
• OLIGONUCLEOTIDE THERAPEUTICS DISCOVERY
• • Discover new developments in single stranded RNAs, non-coding RNAs and non-hepatic cell and tissue targeting
• • Find out what it really takes to bring an oligonucleotide drug to market and learn about the phase-specific strategies you should be implementing
• • Explore emerging solutions to the oligonucleotide delivery challenge and hear the latest preclinical and clinical data to inform your own oligonucleotide therapeutic projects
• PEPTIDE DISCOVERY AND DEVELOPMENT
• • Discover the latest advances in peptide-like scaffolds and structures and peptides as protein-protein interaction modulators to accelerate your discovery efforts
• • Hear new preclinical and clinical data from multiple peptide drugs in development to provide you lessons for your own projects
• • Find novel synthetic approaches to modify peptides and strategies for intracellular peptide delivery to improve the drug-like properties of your molecules
• NUCLEIC ACIDS TECHNOLOGIES FOR MOLECULAR DIAGNOSTICS
• • Learn new technologies for sample prep and for the diagnostics of the future
• • Ensure supply chain for labels and modifications to avoid interruptions in distribution

Share this article with your social network, just click below to share now!

Share |